Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
about
Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
P2860
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en-gb
Subgroup Analyses from a Phase ...... d or Metastatic Breast Cancer.
@nl
type
label
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en-gb
Subgroup Analyses from a Phase ...... d or Metastatic Breast Cancer.
@nl
prefLabel
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en-gb
Subgroup Analyses from a Phase ...... d or Metastatic Breast Cancer.
@nl
P2093
P2860
P50
P356
P1154
2-s2.0-84992088913
P1476
Subgroup Analyses from a Phase ...... ed or Metastatic Breast Cancer
@en
P2093
Ahmad Awada
Chris Twelves
Corina E Dutcus
James Song
Louise Yelle
Martin S Olivo
Peter A Kaufman
P2860
P356
10.4137/BCBCR.S39615
P5530
P577
2016-06-28T00:00:00Z
P6179
1032786490